CJC-1295 / Ipamorelin Protocol
The most commonly discussed growth hormone peptide pairing. This is an educational comparison of what CJC-1295 and Ipamorelin are and why they are mechanistically related, not a protocol to follow.
Educational comparison, not a protocol. This page describes which compounds are commonly discussed together for growth hormone support and the mechanism behind that pairing. It intentionally contains no doses, schedules, injection technique, or cycle structures. Both compounds are research peptides with no established human dosing; any specifics belong with a licensed clinician.
Why These Two Are Discussed Together
CJC-1295 (GHRH analogue)
A Growth Hormone Releasing Hormone (GHRH) analogue. Mechanistically it raises the baseline signal that prompts the pituitary to secrete GH, conceptually the "foundation" layer of the axis.
Ipamorelin (GHRP)
A Growth Hormone Releasing Peptide (GHRP) that acts on a separate receptor to trigger a discrete GH pulse, and is noted in research for doing so without significantly raising cortisol or prolactin.
The complementary rationale: GHRH analogues and GHRPs act on different receptors by different mechanisms, so they are studied as complementary rather than redundant. That mechanistic complementarity is the entire reason the two names appear together, and it is a description of pharmacology, not an endorsement of combining them.
What the Research Does and Does Not Establish
The mechanisms above are reasonably well characterised. What is not established is a validated human protocol: there is no approved label, no agreed dose, and no standardised schedule for either compound in the contexts people discuss. Numbers and cycle structures circulated in communities are not a substitute for that missing clinical evidence.
GH-axis peptides also raise IGF-1, which is exactly why suitability is individual and supervised. The honest educational position is that the pairing is interesting mechanistically and unproven as a self-administered regimen.
Common Questions
Q: Why are CJC-1295 and Ipamorelin discussed together?
A: They act on two different parts of the same growth hormone axis. CJC-1295 is a GHRH analogue that raises the baseline signal for GH release, while Ipamorelin is a GHRP that triggers a discrete GH pulse through a separate receptor. Because the mechanisms are complementary rather than overlapping, the two are frequently studied and discussed as a pair. This is an explanation of the rationale, not a recommendation to combine them.
Q: Does this page give a dose or a cycle schedule?
A: No. We deliberately do not publish doses, frequencies, injection technique, or cycle structures. Those are clinical decisions that depend on the individual and belong with a licensed prescriber. This page explains what the compounds are and why they are mechanistically related, which is the educational part.
Q: Are CJC-1295 and Ipamorelin approved medicines?
A: No. Both are research peptides. They are not approved by Vietnam’s Ministry of Health or the Drug Administration of Vietnam for the uses people discuss, and human dosing is not established by an approved label. Treat any figures seen elsewhere online as community claims, not medical guidance.
Q: What is the difference between CJC-1295 with DAC and without DAC?
A: The DAC (Drug Affinity Complex) modification extends the molecule’s half-life so it circulates far longer, whereas the no-DAC version clears quickly and produces a shorter, more pulse-like signal. This is a pharmacokinetic distinction worth understanding conceptually; it does not translate into a self-administered protocol.
Note: GH-related peptides may increase IGF-1 levels. Elevated IGF-1 is a relevant consideration for anyone with a history of cancer, which is one of several reasons these compounds are only appropriate to evaluate with a qualified physician.
Important Disclaimer
Educational content only. Not medical advice, and not a protocol. This page provides no dosing, schedule, or administration guidance. CJC-1295 and Ipamorelin are not approved by Vietnam's Ministry of Health (Bộ Y Tế) or the Drug Administration of Vietnam (DAV) for the uses described. Consult a licensed physician before considering any use.